Lv4
410 积分 2021-08-10 加入
Long-term outcomes of IgA nephropathy in China
25天前
已完结
Iptacopan in IgA Nephropathy - Final 24-Month Data
1个月前
已完结
Long-term outcomes of IgA nephropathy in China
2个月前
已完结
IgA nephropathy with acute kidney disease: Characteristics, prognosis, and causes
3个月前
已完结
Complement factor H variants are associated with microangiopathy lesions in IgA nephropathy
6个月前
已完结
Q fever endocarditis and glomerulonephritis
6个月前
已完结
Renal Dysfunction and Liver Transplantation
7个月前
已完结
How should we target and reduce the production of pathogenic IgA in IgAN?
10个月前
已完结
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
11个月前
已完结
The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease
11个月前
已完结
皖公网安备34019202002308
